By targeting proteins used to splice genes, UC San Diego researchers have unlocked a new approach to treating triple-negative ...
Significantly longer progression-free survival seen among patients with previously untreated, PD-L1 advanced or metastatic ...
In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread.
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published in Nature ...
A biochemistry assistant professor and graduate student have discovered a new therapeutic target for triple-negative breast cancer.
Gilead has announced full results from its study of Trodelvy (sacituzumab govitecan) plus Keytruda (pembrolizumab) as a first ...
Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the ...
Triple Negative Breast Cancer (TNBC) is one of the most aggresive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...
Health and Me on MSN
Scientists unveil powerful antibody against deadliest breast cancer
Medical University of South Carolina researchers have now developed an antibody that can help fight against triple-negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results